CHI3L1 and neoplasm: Combining the advantages of tumor biomarker blood testing (i.e., relatively simple, non- invasive, and cost-effective) with a more specific tissue-tethered assessment allowed us to provide more representative and clinically-useful data regarding the role of YKL-40 in ASC patient management.